These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22453191)

  • 1. Intranasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers.
    Hardmeier M; Zimmermann R; Rüegg S; Pflüger M; Deuster S; Suter K; Donzelli M; Drewe J; Krähenbühl S; Fuhr P; Haschke M
    Clin Pharmacol Ther; 2012 May; 91(5):856-62. PubMed ID: 22453191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation.
    Wermeling DP; Record KA; Archer SM; Rudy AC
    Epilepsy Res; 2009 Feb; 83(2-3):124-32. PubMed ID: 19046855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers.
    Wermeling DP; Record KA; Kelly TH; Archer SM; Clinch T; Rudy AC
    Anesth Analg; 2006 Aug; 103(2):344-9, table of contents. PubMed ID: 16861415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam.
    Albrecht S; Ihmsen H; Hering W; Geisslinger G; Dingemanse J; Schwilden H; Schüttler J
    Clin Pharmacol Ther; 1999 Jun; 65(6):630-9. PubMed ID: 10391668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers.
    Knoester PD; Jonker DM; Van Der Hoeven RT; Vermeij TA; Edelbroek PM; Brekelmans GJ; de Haan GJ
    Br J Clin Pharmacol; 2002 May; 53(5):501-7. PubMed ID: 11994056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics and EEG effects of midazolam during and after 1-minute, 1-hour, and 3-hour intravenous infusions.
    Greenblatt DJ; Ehrenberg BL; Culm KE; Scavone JM; Corbett KE; Friedman HL; Harmatz JS; Shader RI
    J Clin Pharmacol; 2004 Jun; 44(6):605-11. PubMed ID: 15145968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepam.
    Mould DR; DeFeo TM; Reele S; Milla G; Limjuco R; Crews T; Choma N; Patel IH
    Clin Pharmacol Ther; 1995 Jul; 58(1):35-43. PubMed ID: 7628181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal administration of midazolam: pharmacokinetic and pharmacodynamic properties and sedative potential.
    Fukuta O; Braham RL; Yanase H; Kurosu K
    ASDC J Dent Child; 1997; 64(2):89-98. PubMed ID: 9188997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and tolerability of nasal versus intravenous midazolam in healthy Dutch volunteers: a single-dose, randomized-sequence, open-label, 2-period crossover pilot study.
    Veldhorst-Janssen NM; Fiddelers AA; van der Kuy PH; Theunissen HM; de Krom MC; Neef C; Marcus MA
    Clin Ther; 2011 Dec; 33(12):2022-8. PubMed ID: 22078155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic modeling of electroencephalographic effects of midazolam in eight Chinese men.
    Lu JF; Chen G; Xiang BR; An DK
    Zhongguo Yao Li Xue Bao; 1994 Sep; 15(5):399-403. PubMed ID: 7717060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil.
    Mandema JW; Tukker E; Danhof M
    J Pharmacol Exp Ther; 1992 Jan; 260(1):36-44. PubMed ID: 1309878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation.
    Schrier L; Zuiker R; Merkus FW; Klaassen ES; Guan Z; Tuk B; van Gerven JM; van der Geest R; Groeneveld GJ
    Br J Clin Pharmacol; 2017 Apr; 83(4):721-731. PubMed ID: 27780297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of nasally delivered midazolam.
    Haschke M; Suter K; Hofmann S; Witschi R; Fröhlich J; Imanidis G; Drewe J; Briellmann TA; Dussy FE; Krähenbühl S; Surber C
    Br J Clin Pharmacol; 2010 Jun; 69(6):607-16. PubMed ID: 20565452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans.
    Gudmundsdottir H; Sigurjonsdottir JF; Masson M; Fjalldal O; Stefansson E; Loftsson T
    Pharmazie; 2001 Dec; 56(12):963-6. PubMed ID: 11802661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers.
    Ivaturi VD; Riss JR; Kriel RL; Cloyd JC
    Acta Neurol Scand; 2009 Nov; 120(5):353-7. PubMed ID: 19456308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam.
    Fiset P; Lemmens HL; Egan TD; Shafer SL; Stanski DR
    Clin Pharmacol Ther; 1995 Nov; 58(5):567-82. PubMed ID: 7586951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ketamine racemate or S-(+)-ketamine and midazolam. The effect on vigilance, efficacy and subjective findings].
    Doenicke A; Kugler J; Mayer M; Angster R; Hoffmann P
    Anaesthesist; 1992 Oct; 41(10):610-8. PubMed ID: 1443509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers.
    Bancke LL; Dworak HA; Rodvold KA; Halvorsen MB; Gidal BE
    Epilepsia; 2015 Nov; 56(11):1723-31. PubMed ID: 26332539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal midazolam in piglets: pharmacodynamics (0.2 vs 0.4 mg/kg) and pharmacokinetics (0.4 mg/kg) with bioavailability determination.
    Lacoste L; Bouquet S; Ingrand P; Caritez JC; Carretier M; Debaene B
    Lab Anim; 2000 Jan; 34(1):29-35. PubMed ID: 10759364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects.
    Dingemanse J; van Gerven JM; Schoemaker RC; Roncari G; Oberyé JJ; van Oostenbruggen MF; Massarella J; Segala P; Zell M; Cohen AF
    Br J Clin Pharmacol; 1997 Nov; 44(5):477-86. PubMed ID: 9384465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.